Treatment journey
Get an overview of your patients’ CAR-T treatment journey and learn how to identify patients suitable for CAR-T therapy, refer more efficiently and address needs and concerns of your patients already in treatment.
Selection of patients
referring hospital: Referring hospital: haematologist and oncologist
- Assessing whether the patient is eligible and suitable for CAR T treatment with YESCARTA® in DLBCL
- Informing the patient about CAR T treatment with YESCARTA®
- and managing expectations before referral
Referral
referring hospital: Referring hospital: haematologist, oncologist, and administrative personnel
- Referring the patient to a hospital qualified in YESCARTA®/TECARTUS® treatment
- Seeking approval for the prescription of YESCARTA®/TECARTUS®
- Consideration of bridging therapy for the patient
Pre-Leukapheresis
treating hospital: Treating hospital: haematologist, oncologist, and nurse
- Confirming patient suitability
- Collaboration of the multidisciplinary team
- Coordination with YESCARTA®/TECARTUS® manufacturer Kite
- Providing patients with information and managing expectations
- Planning leukapheresis
Leukapheresis
treating hospital: Treating hospital: apheresis physician and nurse
- Collecting the patient’s lymphocytes through leukapheresis
- Packing the apheresis material for courier collection
Post-leukapheresis
treating hospital: Treating hospital: haematologist and oncologist
- Consideration of bridging therapy for the patient
- Processing of the T cells and engineering of CAR T cells (YESCARTA®/TECARTUS®) by Kite
- Coordination of the delivery date
Conditioning treatment
treating hospital: Treating hospital: haematologist, oncologist, and nurse
- Giving the patient lymphodepleting chemotherapy
Yescarta/Tecartus infusion
treating hospital: Treating hospital: haematologist, oncologist, and cell therapy facility
- Risk management of CRS and neurological events
- Checking patient health and providing information before infusion
- Pre-medicating the patient before infusion
- Checking and preparing the YESCARTA®/TECARTUS® infusion
- Performing the infusion
Monitoring at hospital
treating hospital: Treating hospital: haematologist, oncologist, and nurse
- Daily monitoring to Day 7
- Reporting adverse events
- Instructing patients, relatives, and carers on adverse events
Continued follow up
treating hospital and referring hospital: Treating hospital and referring hospital
- Weekly phone calls from the CAR T treatment team
- First assessment of tumour response
- Handover to the referring physician
- The schedule for follow-up appointments
- Monitoring and reporting adverse events
SE-TEC-0037 | 09/2024
